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Whole exome or whole genome sequencing (WES and WGS, respectively) has dramatically advanced the identification of genetic variants contributing to complex, rare, and clinically heterogeneous human disorders. However, because such variants might be private, it can be challenging to ascribe pathogenicity. Recently, WES and WGS and the international collation of affected individuals with variants in the same gene[@bib1], [@bib2] have led to the identification of several developmental disorders. This approach, referred to as "reverse phenotyping," has been successfully applied to multiple intellectual disability syndromes, including those related to genetic variants in *FBXO11* (MIM: [607871](607871){#intref0010}),[@bib3], [@bib4], [@bib5] and syndromes involving variants in *CDC42* (MIM: [116952](116952){#intref0015}) and *RAC1* (MIM: [602048](602048){#intref0020}),[@bib6], [@bib7] all of which display clinical heterogeneity. Here, we use a similar approach to investigate the role of *de novo* variants in *FBXW11* (MIM: [605651](605651){#intref0025}) in human development.

Through WES of 32 individuals with developmental eye anomalies, we identified a *de novo* missense variant (GenBank: NM_012300.2:c.1087C\>T; NP_036432:p.Arg363Trp) in *FBXW11*. This variant was present in a girl with striking eye anomalies (bilateral microanterior segments, iris and chorioretinal coloboma, and lens anomalies), digital anomalies, and a psychiatric disorder (individual 1) ([Figure 1](#fig1){ref-type="fig"}, [Tables 1](#tbl1){ref-type="table"} and [S1](#mmc1){ref-type="supplementary-material"}, and the [Supplemental Note](#mmc1){ref-type="supplementary-material"}). No other pathogenic variants were present in known eye development genes. Koolen et al.[@bib8] previously described a boy with holoprosencephaly (HPE), seizures, small stature, preaxial polydactyly affecting the hand, "finger-like thumbs," and an increased sandal gap who had a *de novo* duplication encompassing seven genes, including *FBXW11,* on chromosome 5q35.1 (1.24 Mb). They hypothesized that his phenotype could be explained by the duplication of *FBXW11*, given its putative role in hedgehog (Hh) signaling and the phenotypic overlap with other disorders (HPE and polydactyly) caused by dysregulation of this pathway. Furthermore, duplication of the homologous gene *BTRC* (MIM: [603482](603482){#intref0030}) is implicated in split hand-foot malformation.[@bib9] Moreover, FBXW11 participates in the Wnt/β-catenin signaling pathway,[@bib10], [@bib11] which is fundamentally important in eye and brain development[@bib12], [@bib13] and digit patterning.[@bib14]Figure 1Phenotypes of Individuals 1, 2, 4, 5, and 7(A--C) Individual 1 at age 13 years, showing bilateral ptosis related to the underlying ocular anomalies (A), contractures affecting the distal interphalangeal joints of the left 4^th^ and 5^th^ fingers (B), and a wide sandal gap, short terminal phalanges, contractures affecting the 4^th^ and 5^th^ toes, 2--3 toe syndactyly, and scarring from surgery removing the left supernumerary toe (C).(D--I) Individual 1 at age 24 years, showing bilateral microanterior segment and iris colobomas (D--G), contractures of the 4^th^ and 5^th^ left fingers (H), scarring from surgery removing the supernumerary toe, 2--3 toe syndactyly, and contractures of the 4^th^ and 5^th^ toes (I).(J--O) Individual 2 at age 9 years, showing a prominent nasal tip, broad columella, and retrognathia (J--K), the feet showing contractures (see the detailed view of the left 2^nd^ toe), short distal digits, widely spaced toes, left 2--3 toe syndactyly, right 2^nd^ toe clinodactyly (L and M) comparable to that of Individual 1, and MRI scans revealing an abnormal corpus callosum, an absent splenium, thick Probst bundles, small globular dysplastic hippocampi, and mildly reduced white matter volume (N and O).(P--W) Individual 4 at age 18 years, showing dysmorphic facial features including mild ptosis of the upper eyelids, malar hypoplasia, a long and smooth philtrum, a bifid nasal tip, a thin upper lip (P), micrognathia, a tall sloping forehead, and small ears (Q); digital anomalies include shortening of the distal phalanx of the thumbs, 5^th^ finger clinodactyly (R--U), thenar hypoplasia on the right (S), and mild thenar hypoplasia on the left (U); digital anomalies of the feet include shortening of the distal phalanx of the toes and increased convexity of all toenails (V and W).(X--AB) Individual 5 at 4 months, showing a small chin (X), adducted thumbs not well shown as they are held by the clinician (Y and Z), and normal feet (AA and AB).(AC) Individual 7 at 3 years and 2 months, showing frontal bossing; a deep, broad nasal bridge, epicanthus; low-set, posteriorly rotated ears; and a large, protruding tongue.(AD--AJ) Individual 7 at 9 years and 8 months, showing frontal bossing; a deep, broad nasal bridge; epicanthus; low-set, posteriorly rotated ears (AD and AE); mild prognathism (AE); pectus carinatum (AF); and bilateral clinodactyly of the 4^th^ and 5^th^ toes (AG and AH). Brain MRI of Individual 7 showed complete agenesis of the corpus callosum with only a small residual portion of the anterior genum, a retro-cerebellar arachnoidal cyst (AI), and colpocephaly characterized by dilated lateral ventricles, specifically in the occipital and temporal horns and the third ventricle (AJ).Table 1Summary of Phenotypic and Genotypic Data of Individuals with *FBXW11* Missense Variants**Individual1234567Koolen et al. 2006**[@bib8]Variant (GenBank: [NM_012300.2](ncbi-n:NM_012300.2){#intref0230}; NP_036432.2)c.1087C\>T (p.Arg363Trp)c.1091C\>A (p.Ala364Asp)c.1093G\>A (p.Ala365Thr)c.1330G\>A (p.Glu444Lys)c.1340G\>A (p.Arg447Gln)c.1340G\>T (p.Arg447Leu)c.724G\>C (p.Gly242Arg)[1](ncbi-tnm:1){#intref0235}.24Mb duplicationgnomAD[@bib26] frequencyabsentabsentabsentabsentabsentabsentabsentN/AInheritance*de novode novode novode novode novode novode novode novo*InterVar[@bib77] classificationlikely pathogeniclikely pathogeniclikely pathogeniclikely pathogeniclikely pathogeniclikely pathogeniclikely pathogenicN/ASIFT[@bib78] classificationdamagingtolerateddamagingdamagingdamagingtolerateddamagingN/APolyPhen-2[@bib79] classificationprobably damagingprobably damagingprobably damagingpossibly damagingprobably damagingprobably damagingprobably damagingN/ASexfemalemalemalefemalefemalemalemalemaleBirth parametersTerm (weeks \[+days\])40 (+5)4040 (+2)3940 (+6)3838N/AWeight (kg)4.083.633.953.153.173.403.22N/AGrowth parameters (age)Current age (years)2492718189 years, 7 months19Weight in kg (%ile)54 (34^th^ %)33.2 (79^th^ %)75 (68^th^ %)37.5 (0.1^st^ %; −3.7 SD)6.2 (0.1^st^ %; −3.5 SD)30.2 (82^nd^ %)24.5 (8^th^ %)N/AHeight in cm (%ile)169 (81^st^ %)138.4 (81^st^ %)180 (68^th^ %)146.2 (0.5^th^ %; −2.5 SD)66 (2^nd^ %; −2.1 SD)134.5 (86^th^ %)123.5 (2^nd^ %; −2.1 SD)157 (5.5^th^ %) (at 15 years)Head circumference in cm (%ile)58.4 (\>99^th^ %; +3.7 SD)53 (64^th^ %)55.5 (61^st^ %)48.5 (\<1^st^ %; −5.5 SD)[a](#tblfn1){ref-type="table-fn"}N/A57 (\>99^th^ %; +3.5 SD)56 (99^th^ %)57 (92^nd^ %) (at 15 years)Congenital anomaliesFacialyesyesnoyesyesyesyesyesMandibularretrognathiaretrognathianomicrognathiaretrognathianomild prognathismnoOcularbilateral microanterior segment, lens anomalies and colobomas, R microphthalmiasevere strabismusmild myopianoalternating exotropianomild myopianoHandcontractures of the 4^th^ and 5^th^ fingersthinning of R and L thenar musculature, short 5^th^ metacarpal, R transverse palmar crease, and relative brachydactylynothinning of thenar musculature R \> L and short distal phalanges of thumbs, bilateral mild 5^th^ finger clinodactylyno[b](#tblfn2){ref-type="table-fn"}nobrachydactyly, small handsright preaxial polydactyly, finger-like thumbsFootL middle toe polydactyly, wide sandal gaps, 2--3 toe syndactyly, contractures of the L 4^th^ and 5^th^ toesmild 2--3 toe syndactyly, 2^nd^ toe clinodactyly, brachydactyly, wide toe spacing, contractures of the 2^nd^ and 4^th^ toes, short 5^th^ metatarsalnoshort terminal phalanges, wide sandal gapsnonobilateral clinodactyly of the 4^th^ and 5^th^ toes, brachydactyly, small feetwide sandal gapsCardiacnonononopulmonary stenosisnopatent foramen ovaleventricular septal defectrenal or urologicalnonononoR renal hypoplasianonoVURSkeletalnononoyesnonoyesnoDevelopmentMotor delaynomoderatemoderatesevereseveremild to moderatesevereyesIntellectual deficiencynomoderate to severesevereseveredelayed milestonesmoderate to severemoderate to severemildSpeech and language delaynosevereseveresevereN/AmoderatemoderateN/ABehaviorASD or psychiatric featurespsychiatric issuesrepetitive behaviorsclassic autismhand stereotypy, self-injurious, impulsive and aggressive behaviorN/AASD, anxietyself-injurious, impulsive and aggressive behaviorN/ANeurological featuresTonenormalincreasedincreasednarrow based gaitcerebral palsylowlowincreasedSeizures or EEG activityN/Amild slowing of cerebral activitynormalN/AN/AN/Anormalinfrequent seizuresMRIN/Ahypoplasia of the corpus callosum, reduced white matter, abnormal hippocampiN/Anormalgeneralized white matter atrophy, periventricular white matter changes with ischemic damagemild prominence of lateral ventricleshypoplasia of the corpus callosum, mild prominence of lateral ventricleslobar HPE, hypoplasia of the corpus callosumOther relevant findingsnoneumbilical and inguinal herniasnonehyperkineticcirculatory collapse at few days of agedermal melanosis, cupped earswebbed neck, bilateral cryptorchidismN/A[^2][^3][^4]

Through GeneMatcher,[@bib2] we identified six other individuals with *de novo* missense variants in *FBXW11*; all were predicted to be damaging and found by WES or WGS. Five individuals (individuals 2--6) exhibited neurodevelopmental and/or digit anomalies, and one (individual 7) had a complex phenotype including brain anomalies and features suggestive of Noonan syndrome ([Tables 1](#tbl1){ref-type="table"} and [S1](#mmc2){ref-type="supplementary-material"}, [Figure 1](#fig1){ref-type="fig"}, and the [Supplemental Note](#mmc1){ref-type="supplementary-material"}). Individual 7 had no pathogenic variants in genes currently included in Noonan syndrome or related RASopathy diagnostic panels. All genetic testing was performed under research ethics approval from the UK "Genetics of Eye and Brain anomalies" study (REC 04/Q0104/129), French (CPP Sud-Ouest and Outre-Mer II), American (Duke University, Pro00032301 - Genomic Study of Medical, Developmental, or Congenital Problems of Unknown Etiology), and Italian (Ospedale Pediatrico Bambino Gesù study 1702_OPBG_2018) ethics committees or by clinical diagnostic consent ([Supplemental Material and Methods](#mmc1){ref-type="supplementary-material"}).

Our seven individuals presented with a range of overlapping phenotypes. Neurodevelopmental features commonly included neurodevelopmental delay (6/7), speech delay (5/7), autistic and/or stereotypical behaviors (3/7), psychiatric features (4/7), and micro- (1/7) or macrocephaly (3/7). MRI data from five individuals indicated corpus callosal hypoplasia (2/5), dilated ventricles (2/5), and white matter atrophy (2/5). Five of seven individuals had an under- or overdeveloped jaw. Digital anomalies were striking and included brachydactyly or short distal phalanges (3/7), polysyndactyly (2/7), widened interdigital spaces and/or sandal gap (2/7), camptodactyly or contractures (2/7), and underdeveloped thenar musculature (2/7). Individual 7 was clinically diagnosed with Noonan syndrome, and pulmonary stenosis, a recurrent feature of this disorder, was present in individual 5. Only individual 1 had developmental eye anomalies. Certain of these phenotypes overlap with those of the boy, presented by Koolen et al.,[@bib8] who exhibited multiple digital anomalies, neurodevelopmental delay, and absence of the anterior part of the corpus callosum. From the published images, it also appears that he has broad halluces and short terminal phalanges. The latter are interesting because individual 4 had bilateral shortening of the thumbs and big toes, individuals 2, 4, and 7 had short terminal phalanges and/or brachydactyly, and individuals 2 and 4 had underdevelopment of the thenar eminence, akin to "finger-like thumbs." Although overlapping features can be seen, there is phenotypic diversity, which appears to be an emerging pattern for variants affecting genes controlling multiple cellular pathways and developmental processes; these gene include, for example, *CDC42*,[@bib6] *FBXO11*,[@bib3], [@bib4], [@bib5] *SHH* (MIM: [600725](600725){#intref0035}),[@bib15], [@bib16] and *SOX2* (MIM: [184429](184429){#intref0040}).[@bib17], [@bib18]

FBXW11 belongs to a highly conserved group of around 60 proteins characterized by a motif of ∼40 amino acids (the F-box). This family is subdivided into three classes: FBXWs containing WD40 repeats, FBXLs containing leucine-rich repeats, and FBXOs containing either different protein-protein interaction modules or no recognizable motifs.[@bib19] WD40-repeats are also a motif of approximately 40 amino acids and typically fold into a β-propeller structure that is involved in protein-protein interaction.[@bib20], [@bib21] Alterations in other F-box genes, for example *FBXO11*[@bib3], [@bib4], [@bib5] and *FBXL4* (MIM: [605654](605654){#intref0045}), have been associated with neurodevelopmental disorders.[@bib22] FBXW11 is a substrate adaptor of the Skp1-cullin-F-box (SCF) ubiquitin ligase complex, which catalyzes phosphorylation-dependent ubiquitination.[@bib11], [@bib23] It has several targets, including β-catenin and GLI transcription factors, key mediators of the Wnt and the Hh pathways, respectively. Despite the importance of these two pathways, little is known about the role of *FBXW11* in human development and the impact of aberrant FBXW11 function on human disease.

Different *in silico* metrics indicate that *FBXW11* is moderately intolerant to variation.[@bib24], [@bib25] It has a Residual Variation Intolerance Score (RVIS) of −0.47, ranking it among the 23% of human protein-coding genes most intolerant to functional (missense, nonsense, and splice) variants.[@bib24] Moreover, metrics reported on gnomAD (v2.1.1)[@bib26] suggest it is intolerant to both loss-of-function (LoF) variants (observed/expected \[o/e\] score = 0.15, 0.08--0.31 90% confidence interval \[CI\]; pLI score = 0.98) and missense variants (o/e score = 0.37, 0.32--0.43 90% CI; *Z* score = 3.96). The latter is of particular relevance because all the *de novo* variants in this study are missense changes. In addition to these seven variants, two further *de novo* changes of uncertain clinical significance in *FBXW11* have been reported in large scale studies of autism spectrum disorder (ASD) (GenBank: NM_012300.2:c.243C\>G \[p.Asp81Glu\]; dbSNP: rs995419585, c.508C\>T \[p.Arg170Ter\]).[@bib27], [@bib28] None of these nine variants or other changes affecting these amino acids were listed on gnomAD, with the exception of a rare synonymous variant for Ala365 (dbSNP: rs775168567, GenBank: NM_012300.2:c.1095C\>T, minor allele frequency \[MAF\] = 0.00001771) and a missense change for Arg170 (dbSNP: rs995419585, GenBank: NM_012300.2:c.508C\>G \[p.Arg170Gly\], MAF = 0.000003984). Furthermore, the nucleotide positions affected by our seven missense variants are evolutionarily conserved according to the GERP rejected substitutions scores[@bib29], [@bib30] ([Table S1](#mmc2){ref-type="supplementary-material"}). Interestingly, these variants are located in regions depleted for nonsynonymous variation ([Figure S1](#mmc1){ref-type="supplementary-material"}). According to the model developed by Havrilla et al.,[@bib31] six of the seven missense changes affect residues located within portions of the protein considered as under the highest constraint in the human genome, ranking among the top 5% constrained coding regions (CCRs). The amino acid substitution (c.724G\>C \[p.Gly242Arg\]) in individual 7, who presented with features of Noonan syndrome, is located in a region characterized by a slightly lower level of constraint (85^th^ percentile). Therefore, the location of the variants in these regions further supports their potential relevance to protein function.

Intriguingly, all seven missense variants affected the WD40 domain of FBXW11 ([Figure 2](#fig2){ref-type="fig"}). In particular, six of the seven changes appeared to cluster at the N-terminal end of the WD4 (residues 363 to 365, in individuals 1, 2, and 3, affecting consecutive amino acids) and WD6 (residues 444 and 447, in individuals 4, 5, and 6 \[individuals 5 and 6 had the same affected amino acid\]) repeats. The seventh variant (in individual 7) affected the N-terminal end of the WD1 repeat. In contrast with this specific distribution, the two variants reported in the ASD-affected individuals[@bib27], [@bib28] either affected a different domain of FBXW11 (p.Asp81Glu, homodimerization domain), or resulted in a truncated, likely inactive, protein (p.Arg170Ter).Figure 2Structural Modeling of *FBXW11* Missense Variants(A) A schematic representation of FBXW11 showing the relative locations of the homodimerization domain D (Hd D, blue), F-box (red), WD40 domains (green), and the missense variants identified in our seven individuals.(B) A Clustal Omega alignment of the FBXW11 regions containing the variants identified in this study showing affected amino acids highlighted in yellow and complete conservation across species.(C) A homology model of FBXW11 in complex with Skp1 and β-catenin based on PDB structure PDB: [1P22](pdb:1P22){#intref0225}. Skp1 is shown in blue, β-catenin in orange, and the FBXW11 domains in red (F-box), green (linker region), and gray (WD40 domains).(D) The locations of the amino acids affected by the *FBXW11* variants within the WD40 domain. β-catenin is shown in orange.(E) The modeled WD40 domain of FBXW11 in complex with β-catenin (orange) and other available peptides known to bind FBXW7 or Cdc4 (cyclin E C-terminal degron, cyclin E N-terminal degron, DISC1, high-affinity CPD phosphopeptide from human cyclin E, SIC1).

No protein structure for FBXW11 was available in the Research Collaboratory for Structural Bioinformatics Protein Data Bank (RCSB PDB).[@bib32] However, an experimentally derived crystal structure for a homolog, BTRC, complexed with Skp1 and β-catenin was available (PDB: [1P22](pdb:1P22){#intref0050}).[@bib20] Pairwise alignment of BTRC (GenBank: [NP_003930.1](ncbi-p:NP_003930.1){#intref0055}) and FBXW11 (GenBank: [NP_036432.2](ncbi-p:NP_036432.2){#intref0060}) show the proteins have 79.0% identity and 87.4% similarity, and the regions containing the missense variants in individuals 1--7 were highly conserved ([Figure S2](#mmc1){ref-type="supplementary-material"}). Therefore, we modeled a 3D structure for FBXW11 (GenBank: [NP_036432.2](ncbi-p:NP_036432.2){#intref0065}) based on the crystal structure of BTRC, employing a previously described procedure.[@bib33] The location of the affected residues was visualized with PyMOL v2.0 (the PyMOL Molecular Graphics System, Version 2.0 Schrödinger). Notably, all affected residues were located toward the tips of the loops of the WD repeat domains, which are predicted to mediate substrate binding ([Figure 2](#fig2){ref-type="fig"}). Because there is high conservation of the WD repeat structure, and because each repeat contacts β-catenin,[@bib20] all seven altered residues are expected to impact substrate binding. Clustering of the *de novo* missense variants suggests an impact on protein function via gain-of-function or dominant-negative mechanisms.[@bib34] Despite this, and the fact that the phenotypes of these individuals fall in broad, overlapping categories, there is variation in the specifics of their features. We modeled the WD40 domain of FBXW11 bound to substrates of the WD40-domain-containing proteins FBXW7 and Cdc4 ([Figure 2](#fig2){ref-type="fig"}E). This indicated that individual substrates might adopt different orientations when binding to FBXW11, suggesting a variable contribution of the different WD40 motifs in FBXW11 binding to individual ligands. Therefore, it is possible that the missense variants identified here might have varying impacts depending on the substrate.

We investigated the impact of the missense variants on protein stability and interaction with Skp1 and β-catenin for both our modeled FBXW11 structure and BTRC by using FoldX.[@bib35] Predictions indicated five of the seven missense variants (c.1087C\>T \[p.Arg363Trp\]; c.1091C\>A \[p.Ala364Asp\]; c.1093G\>A \[p.Ala365Thr\]; c.1340G\>A \[p.Arg447Gln\]; and c.724G\>C \[p.Gly242Arg\]) impact the stability of both FBXW11 and BTRC ([Table 2](#tbl2){ref-type="table"}). Furthermore, five of the variants (p.Ala364Asp, p.Ala365Thr, p.Arg447Gln, p.Arg447Leu, and p.Gly242Arg) were predicted to decrease the stability of the FBXW11-β-catenin and BTRC-β-catenin interactions. Three variants (p.Ala365Thr, p.Arg447Leu, and p.Gly242Arg) also decreased the stability of the FBXW11-Skp1 and BTRC-Skp1 interactions ([Table 2](#tbl2){ref-type="table"}). Interestingly, the variant (p.Gly242Arg) in individual 7, who presented with features of Noonan syndrome, was predicted to have the greatest impact on both FBXW11 and BTRC stability and their interactions with β-catenin and Skp1. On the basis of these analyses, the variants are predicted to produce variable downstream effects and resultant phenotypes, particularly because FBXW11 is involved in multiple developmental pathways.Table 2FoldX Predictions of the Impact on FBXW11 and BTRC Stability and Their Interactions with Skp1 and β-catenin of the *FBXW11* Variants Identified in Individuals 1--7**Individual1234567**Variantp.Arg363Trpp.Ala364Aspp.Ala365Thrp.Glu444Lysp.Arg447Glnp.Arg447Leup.Gly242ArgFBXW11FBXW11ΔΔG0.5216094.090864.12764−0.01597211.636510.124612.0844Stabilityminor decreasedecreasedecreasenonedecreasenonedecrease+ Skp1ΔΔG0.00.00.4820.00.00.90229.6142Stabilitynonenoneminor decreasenonenoneminor decreasedecrease+ β-cateninΔΔG0.127824.9439623.866386−0.379362.29311.5526610.19112StabilitynonedecreasedecreasenonedecreasedecreasedecreaseBTRCBTRCΔΔG0.517284.474953.59842−0.100021.545550.018667210.264Stabilityminor decreasedecreasedecreasenonedecreasenonedecrease+ Skp1ΔΔG0.00.00.65720.00.00.73188.8664Stabilitynonenoneminor decreasenonenoneminor decreasedecrease+ β-cateninΔΔG0.143825.787233.457756−0.331982.2793821.52149.16596Stabilitynonedecreasedecreasenonedecreasedecreasedecrease[^5]

Next, we determined the expression profile of *FBXW11* during human development by using nonradioactive RNA *in situ* hybridization on human embryo sections from Carnegie Stages (CS) 15--21, obtained from the MRC/Wellcome Trust Human Developmental Biology Resource, UCL, with full ethical approval.[@bib36] We designed two probes to target all three *FBXW11* human isoforms (GenBank: [NM_012300](ncbi-n:NM_012300){#intref0070}, [NM_033644](ncbi-n:NM_033644){#intref0075}, and [NM_033645](ncbi-n:NM_033645){#intref0080}) ([Supplemental Material and Methods](#mmc1){ref-type="supplementary-material"}). Both probes showed similar expression patterns ([Figure 3](#fig3){ref-type="fig"}, [Figure 4](#fig4){ref-type="fig"}, [Figure 5](#fig5){ref-type="fig"} and [S3--S6](#mmc1){ref-type="supplementary-material"}).Figure 3*In Situ* Hybridization Studies Showing *FBXW11* Expression During Human Eye Development(A--E) Sagittal sections of the eye at CS15 (A), CS17 (B), CS19 (C), CS20 (D), and CS21 (E) made by using the 5′ UTR probe showing a strong *FBXW11* signal in the lens (A--C), the retina (A--E), the lips of the optic fissure closure (B), and regions of the developing conjunctiva (C and E). As eye development progresses, the stronger signal observed in the retina progressively shifts from the inner toward the outer retinal layers (A--D). Abbreviations are as follows: Cj = conjunctiva; HV = hyaloid vasculature; Ls = lens; OF = optic fissure; and Rn = retina.

In the eye, *FBXW11* expression was seen throughout the lens at multiple time points ([Figures 3](#fig3){ref-type="fig"}A--3C, [S3](#mmc1){ref-type="supplementary-material"}A--S3F, S3I, and S3J), a fact of particular relevance to the congenitally absent and thin lenses in individual 1. In the retina, *FBXW11* expression appeared to shift over time from the inner to outer neuroretinal cell layers ([Figures 3](#fig3){ref-type="fig"}A--3D). Sagittal sections of the eye at CS17 also showed *FBXW11* expression at the margins of the optic fissure ([Figures 3](#fig3){ref-type="fig"}B, [S3](#mmc1){ref-type="supplementary-material"}C, and S3D), indicating a potential role in optic fissure closure, relevant to the bilateral chorioretinal colobomas in individual 1. Expression of *FBXW11* was also seen in the developing conjunctiva ([Figures 3](#fig3){ref-type="fig"}C, 3E, and [S3](#mmc1){ref-type="supplementary-material"}E--S3J).

In the developing hand, expression of *FBXW11* was analyzed in parallel with expression of the chondrogenic marker *SOX9* (MIM: [608160](608160){#intref0085}).[@bib37] At CS15, a strong signal was detected for both genes ([Figures 4](#fig4){ref-type="fig"}A, 4B, [S4](#mmc1){ref-type="supplementary-material"}A, and S4B); *FBXW11* displayed more widespread expression throughout the limb bud compared with the restricted expression pattern of *SOX9*. At CS19 and CS21, after the digits have begun to form, strong *FBXW11* expression was seen in the mesenchyme surrounding the developing cartilage ([Figures 4](#fig4){ref-type="fig"}C--4J and [S4](#mmc1){ref-type="supplementary-material"}C--S4J). Interestingly, digital anomalies were observed in four of the individuals we report, as well as the boy reported by Koolen et al.[@bib8]Figure 4*In Situ* Hybridization Studies Comparing *FBXW11* and *SOX9* Expression During Human Limb Development(A--J) Coronal sections of the forelimb at different CS stages showing the expression pattern of *FBXW11* (5′ UTR probe) on the left (A, C, E, G, and I) and the chondrogenic marker *SOX9* on the right (B, D, F, H, and J). E, F, I, and J show increased magnification of the boxed regions at CS19 (C and D) and CS21 (G and H) highlighting *FBXW11* expression around the developing cartilage of the digits in the hand plate.

In the brain, *FBXW11* expression was present in the primitive ventricles (CS17 and CS19, [Figures 5](#fig5){ref-type="fig"}A--5C, [S5](#mmc1){ref-type="supplementary-material"}A, S5B, [S6](#mmc1){ref-type="supplementary-material"}A, and S6 B), metencephalon (CS19, [Figures 5](#fig5){ref-type="fig"}C, [S5](#mmc1){ref-type="supplementary-material"}B, and [S6](#mmc1){ref-type="supplementary-material"}B), hypothalamus (CS17, [Figure 5](#fig5){ref-type="fig"}D), and medulla (CS17, [Figure 5](#fig5){ref-type="fig"}E). These expression patterns are consistent with the altered brain structure, including prominence of the lateral ventricles and periventricular changes, of individuals 2, 5, 6, and 7. Furthermore, this finding supports an important role for FBXW11 in pathways, including the Hh and the Wnt cascades, essential for normal brain development.[@bib38], [@bib39] Strong expression was also observed in the pharyngeal arches, including the mandibular process and tongue (CS17, [Figures 5](#fig5){ref-type="fig"}F, [S5](#mmc1){ref-type="supplementary-material"}C, and [S6](#mmc1){ref-type="supplementary-material"}C). Expression in these structures might relate to the micrognathia or retrognathia of four of the reported individuals (1, 2, 4, and 5) and the large tongue in individual 7. Other structures showing expression included: the adrenal glands (CS17, [Figures 5](#fig5){ref-type="fig"}G, [S5](#mmc1){ref-type="supplementary-material"}D, and [S6](#mmc1){ref-type="supplementary-material"}D), the lungs (CS17 and CS21, [Figures 5](#fig5){ref-type="fig"}G, 5H, [S5](#mmc1){ref-type="supplementary-material"}E, and [S6](#mmc1){ref-type="supplementary-material"}E), the pulmonary artery and dorsal aorta (CS21, [Figures 5](#fig5){ref-type="fig"}I, [S5](#mmc1){ref-type="supplementary-material"}F, and [S6](#mmc1){ref-type="supplementary-material"}F), the liver (CS15, [Figures 5](#fig5){ref-type="fig"}J, [S5](#mmc1){ref-type="supplementary-material"}G, and [S6](#mmc1){ref-type="supplementary-material"}G), the spleen (CS15, [Figures 5](#fig5){ref-type="fig"}J, [S5](#mmc1){ref-type="supplementary-material"}G, and [S6](#mmc1){ref-type="supplementary-material"}G), and the midgut (CS17, [Figures 5](#fig5){ref-type="fig"}K, [S5](#mmc1){ref-type="supplementary-material"}H, and [S6](#mmc1){ref-type="supplementary-material"}H); the dorsal ganglia (CS21, [Figures 5](#fig5){ref-type="fig"}L, [S5](#mmc1){ref-type="supplementary-material"}I, and [S6](#mmc1){ref-type="supplementary-material"}I) and the spinal cord (CS15, [Figures 5](#fig5){ref-type="fig"}J, [S5](#mmc1){ref-type="supplementary-material"}G, and [S6](#mmc1){ref-type="supplementary-material"}G; CS17 [Figures 5](#fig5){ref-type="fig"}A, [S5](#mmc1){ref-type="supplementary-material"}A, and [S6](#mmc1){ref-type="supplementary-material"}A; and CS21, [Figures 5](#fig5){ref-type="fig"}M, [S5](#mmc1){ref-type="supplementary-material"}J, and [S6](#mmc1){ref-type="supplementary-material"}J), where the signal was detected in the floor plate, the roof plate, and the ventricular and intermediate layers of the spinal cord (CS21, [Figures 5](#fig5){ref-type="fig"}M, [S5](#mmc1){ref-type="supplementary-material"}J, and [S6](#mmc1){ref-type="supplementary-material"}J). The expression in the pulmonary artery and dorsal aorta is interesting given the pulmonary stenosis seen in individual 5.Figure 5*In Situ* Hybridization Studies of *FBXW11* in the Human Showing the Expression Pattern in Multiple Structures during Embryonic DevelopmentExperiments performed using the 5′ UTR probe. Structures of interest are indicated by arrows.(A) A sagittal section of embryo at CS17 (week 6), showing *FBXW11* expression in multiple developing structures.(B) A sagittal section of the head at CS17 (week 6) indicating expression in the structures forming the lateral, third, and fourth ventricles.(C) A sagittal section of the head at CS19 (week 7) showing strong expression in the regions surrounding the lateral ventricle and the metencephalon.(D--G) Increased magnification of structures from (A) highlighting *FBXW11* expression in the hypothalamus (D), lower medulla (E), pharyngeal arches (F), and the adrenal glands and lungs (G).(H) A coronal section at CS21 (week 8) showing expression in the lungs.(I) A coronal section of the heart at CS21 showing *FBXW11* expression in the dorsal aorta and the pulmonary artery.(J) A sagittal section of the embryo at CS15 (week 5) highlighting strong *FBXW11* expression in the liver, spleen, and spinal cord.(K) Increased magnification of (A) showing *FBXW11* expression in the midgut.(L) A transverse section at CS21 showing a strong *FBXW11* signal in the dorsal ganglia.(M) A transverse section of the spinal cord at CS21 showing *FBXW11* expression in the floor plate, roof plate, and the ventricular and the intermediate layers of the spinal cord.Abbreviations are as follows: AG = adrenal glands; AP = alar plate; BP = basal plate; DA = dorsal aorta; DG = dorsal ganglia; Es = Esophagus; FP = floor plate; FV = fourth ventricle; Hp = hypothalamus; IL = intermediate layer; Lg = lungs; Li = liver; LV = lateral ventricle; Md = medulla; Me = metencephalon; Mg = midgut; ML = marginal layer; MP = mandibular process; PA = pulmonary artery; Par = pharyngeal arches; RP = roof plate; SC = spinal cord; Sp = spleen; St = stomach; To = tongue; TV = third ventricle; VL = ventricular layer; and Vt = vertebra.

The zebrafish genome includes two orthologs of *FBXW11*, *fbxw11a* and *fbxw11b*. These genes encode proteins with 90.4% sequence identity and 95.3% similarity. Furthermore, both zebrafish orthologs share around 85% identity and 91% similarity with human FBXW11 (GenBank: [NP_036432.2](ncbi-p:NP_036432.2){#intref0090}) (Fbxw11a \[GenBank: [NP_958467.1](ncbi-p:NP_958467.1){#intref0095}\]: 84.7% identity, 90.6% similarity; Fbxw11b \[GenBank: [NP_998669.2](ncbi-p:NP_998669.2){#intref0100}\]: 85.6% identity, 91.2% similarity). We performed *in situ* hybridization with probes designed against the low homology 3′ UTR region of *fbxw11a* and *fbxw11b* to avoid cross-detection ([Supplemental Material and Methods](#mmc1){ref-type="supplementary-material"}).[@bib40] At 4 days post fertilization (dpf), *fbxw11a* is expressed at low levels in the retina and brain and higher levels in the jaw mesenchyme ([Figure 6](#fig6){ref-type="fig"}A). *fbxw11b* is expressed widely in the brain and eyes, and there are high levels in the retinal ganglion layer, inner nuclear layer, in or adjacent to the outer plexiform layer, in the photoreceptor layer, ciliary marginal zone, jaw mesenchyme, oral epithelia ([Figure 6](#fig6){ref-type="fig"}B), and pectoral fins ([Figures S7](#mmc1){ref-type="supplementary-material"}A--S7D). These findings are comparable to the expression data in humans, further supporting a role for *FBXW11* in the development of the eye, jaw, limbs, and brain.Figure 6*fbxw11a* and *fbxw1b* Are Expressed in the Zebrafish Eye, and Their Knockdown Leads to Abnormal Eye and Jaw Development(A and B) Coronal plastic sections showing the expression pattern of *fbxw11a* (A) and *fbxw11b* (B) in 4dpf zebrafish heads detected by *in situ* hybridization. Dorsal is up. The scale bar in (A) is 100μm.(C) Diagram of human FBXW11 and zebrafish Fbxw11b and Fbxw11b^**u5010**^. The βTrCP domain is in blue, the F-box domain is in green, the seven WD40 domains are in yellow, and the nonsense sequence of Fbxw11b^**u5010**^ is in red. The numbers are amino acid positions in respective proteins.(D--I) 3dpf live zebrafish *MZfbxw11*^***u5010/u5010***^ (D, E, H, and I) and *MZfbxw11b*^***+/u5010***^ (F and G) embryos injected with 500pg of control (D and E) or *fbxw11a* (F--I) morpholinos. Lateral (D, F, and H) and dorsal (E, G, and I) view, both anterior to left. The scale bar in (D) is 400μm and in (E) is 200μm.(J--Q) 5dpf zebrafish *MZfbxw11b*^***+/u5010***^ (J, K, N, and P) and *MZfbxw11*^***u5010/u5010***^ (L, M, O, and Q) embryos injected with 500pg *fbxw11a* morpholino. (J--M) Live embryos lateral (J and L) and dorsal (K and M) view, both anterior to left. The scale bar in (J) is 400μm and in (K) is 200μm.(N and O) Confocal imaging of DAPI-stained coronal plastic sections. The scale bar in (N) is 100μm.(P and Q) Alcian blue staining of cartilage structures. Ventral view, anterior to left. The scale bar in (P) is 200μm.Abbreviations are as follows: Aq = aqueous humor; bh = basihyal; ch = ceratohyal; CMZ = ciliary marginal zone; hs = hyosymplectic; INL = inner nuclear layer; IPL = inner plexiform layer; mc = Meckel's cartilage; ONL = outer nuclear layer; OPL = outer plexiform layer; pq = palatoquadrate; PR = photoreceptor layer; and RGL, retina ganglion layer.

To further investigate the role of *FBXW11* in vertebrate development, we generated zebrafish knockdown models by using a combination of morpholino and CRISPR-Cas9 technologies ([Supplemental Material and Methods](#mmc1){ref-type="supplementary-material"}). Morpholino knockdown of *fbxw11a* resulted in no overt phenotype in zebrafish embryos ([Figures S7](#mmc1){ref-type="supplementary-material"}E and S7F). *fbxw11b* morphants consistently showed reduced eye size and a shorter and bent axis phenotype ([Figures S7](#mmc1){ref-type="supplementary-material"}E and S7G). Because morpholinos can have off-target effects, using CRISPR-Cas9 we induced a 7bp frameshift mutation (allele u5010, p.Asp24Leufs^∗^6) in *fbxw11b* exon 2 ([Figures 6](#fig6){ref-type="fig"}C and [S7](#mmc1){ref-type="supplementary-material"}H--S7K). *fbxw11b*^*u5010/u5010*^ homozygous embryos showed no abnormal phenotype and were viable and fertile. Maternal zygotic (MZ) mutant *fbxw11b*^*u5010/u5010*^ embryos from an *fbxw11b*^*u5010/u5010*^ female to *fbxw11b*^*+/u5010*^ male cross also showed no abnormal phenotype ([Figures 6](#fig6){ref-type="fig"}D and 6E).

We hypothesized that compensation by *fbxw11a* could result in the absence of phenotype in *MZfbxw11b*^*u5010/u5010*^ embryos. For instance, recent studies have shown that the loss of function of a gene resulting from nonsense-mediated decay (NMD) might be compensated for by altered expression of other genes.[@bib41], [@bib42], [@bib43] Because our CRISPR-Cas9 *fbxw11b* mutant carries a frameshift mutation, it might be subject to NMD. Therefore, the lack of phenotype observed might be a result of compensatory gene expression, possibly by *fbxw11a*. However, *in situ* hybridization experiments did not show any obvious upregulation of *fbxw11a* in *fbxw11b* mutants at 48 h post fertilization (hpf) (not shown). Therefore, the basal level of expression of *fbxw11a* might be sufficient to compensate for the lack of function of *fbxw11b*. To begin to address this issue, we injected *fbxw11a* morpholino (mo^*fbxw11a*^) in *MZfbxw11b*^*u5010/u5010*^ and sibling embryos. No overt phenotype was generated before 2dpf in any genotype, and no phenotype was observed in morpholino-injected heterozygous or wild-type siblings at any stage examined. By 3dpf, *MZfbxw11b*^*u5010/u5010*^*/mo*^*fbxw11a*^ morphants showed abnormally developed pectoral fins and heart edema ([Figures 6](#fig6){ref-type="fig"}D--6I, n = 20/21); this is of interest given the digital anomalies in the individuals presented here. At 5dpf, *MZfbxw11b*^*u5010/u5010*^*/mo*^*fbxw11a*^ morphant knockdown embryos developed periocular edema and smaller eyes compared to *MZfbxw11b*^*+/u5010*^*/mo*^*fbxw11a*^ knockdown heterozygous siblings ([Figures 6](#fig6){ref-type="fig"}J--6M, n = 20/20). Coronal sections showed that 5dpf *MZfbxw11b*^*u5010/u5010*^*/mo*^*fbxw11a*^ knockdown eyes had all the retinal layers present in the wild-type; however, the eye was smaller and misshapen. This was potentially because of a lack of aqueous humor in *MZfbxw11b*^*u5010/u5010*^*/mo*^*fbxw11a*^ knockdowns, although it was present in the phenotypically normal siblings at the same stage ([Figures 6](#fig6){ref-type="fig"}N and 6O). The reduction in eye size in mutant knockdown fish supports a role for *FBXW11* in eye development and supports the *FBXW11* variant's being implicated in the microphthalmia observed in individual 1. Alcian blue cartilage staining in *MZfbxw11b*^*u5010/u5010*^*/mo*^*fbxw11a*^ knockdowns revealed abnormal development of the jaw ([Figures 6](#fig6){ref-type="fig"}P and 6Q). The basihyal (pharyngeal arch) cartilage structure protruded anteriorly in *MZfbxw11b*^*u5010/u5010*^*/mo*^*fbxw11a*^ knockdowns because of shorter Meckel's and palatoquadrate cartilages ([Figures 6](#fig6){ref-type="fig"}P and 6Q). These latter observations are consistent with four of our individuals presenting with retrognathia or micrognathia.

*FBXW11* has been shown to negatively regulate the Wnt/β-catenin pathway.[@bib44] Inhibition of Wnt/β-catenin signaling is required for the correct specification of forebrain territories, and enhanced Wnt activity leads to embryos with smaller or no eyes.[@bib45], [@bib46] Enhanced Wnt activity in *tcf7l1a* mutants results in a smaller eye field and reduced eye size by 32hpf.[@bib47] To determine whether Wnt/β-catenin signaling was affected in *fbxw11b*^*u5010/u5010*^ embryos, we assessed whether there were any genetic interactions between the mutated forms of *fbxw11b* and *tcf7l1a*. As previously shown,[@bib47] *tcf7l1a*^*−/−*^ eyes were close to 50% of the size of wild-type eyes ([Figure S8](#mmc1){ref-type="supplementary-material"}A). However, *fbxw11b* ^*u5010/u5010*^*/tcf7l1a*^*−/−*^ double mutant embryos developed even smaller eyes, about 80% of the size of eyes in *tcf7l1a* embryos ([Figure S8](#mmc1){ref-type="supplementary-material"}A, p = 0.0001, *tcf7l1a*^*−/−*^ embryos, $\widetilde{x}$ = 910.337μm^3^ ± 118e[@bib3] n = 20; *fbxw11b* ^*u5010/u5010*^*/tcf7l1a*^*−/−*^ embryos, $\widetilde{x}$ = 727.588 ± 145e,[@bib3] n = 19). This suggests that abrogation of *fbxw11b* leads to further enhanced Wnt signaling in *tcf7l1a*^*−/−*^ mutants. Furthermore, exposure of embryos to a low dose of the Wnt/β-catenin agonist BIO (0.5μm treatment from 24hpf onward) led to an upward bent trunk in *fbxw11b*^*u5010/u5010*^*/mo*^*fbxw11a*^ knockdown embryos but not in *fbxw11b*^*u5010/u501*^ or wild-type embryos ([Figures S8](#mmc1){ref-type="supplementary-material"}B--S8D, 100% n = 13, two experiments). This morphology is similar to that observed in APC mutants in which the Wnt pathway is constitutively overactivated.[@bib48] Overall, these results suggest that the *fbxw11b*^*u5010/u5010*^*/mo*^*fbxw11a*^ knockdown embryos are sensitized to the effects of enhanced Wnt/β-catenin activity.

Given the phenotype of individual 1 and our *in situ* and zebrafish data, we further explored whether *FBXW11* variants contribute more widely to developmental eye disorders by performing targeted screening in an additional 263 individuals with anophthalmia, microphthalmia, or coloboma (AMC) by using high-resolution melt curve analysis[@bib49] or Sanger sequencing ([Supplemental Material and Methods](#mmc1){ref-type="supplementary-material"}). Excluding three 3′ UTR private variants (c.^∗^4064\_^∗^4065insT \[chr5:171,288,698--171,288,699\], c.^∗^2867G\>A \[chr5:171,289,855\], c.^∗^2592C\>T \[chr5:171,290,168\]; GenBank: [NM_012300.2](ncbi-n:NM_012300.2){#intref0105}, GRCh37/hg19) inherited from unaffected parents, no functionally relevant variants were identified. Similarly, array comparative genome hybridization (aCGH) analysis of 77 individuals, including individual 1, with isolated or syndromic AMC did not identify any copy number aberrations affecting *FBXW11*. This indicates variants in *FBXW11* might only rarely be associated with human AMC.

FBXW11 is involved in multiple developmental pathways, including Wnt signaling, which plays a crucial role in the regulation of cell proliferation, tissue patterning, and organ morphogenesis. Wnt signaling can be divided into canonical and non-canonical pathways; and a key element of the former is ubiquitination of β-catenin ([Figures S9](#mmc1){ref-type="supplementary-material"}A and S9B).[@bib10], [@bib50] This ubiquitination, controlled by the SCF complex, is directed either by BTRC or its paralog BTRC2, encoded by *BTRC* and *FBXW11*, respectively.[@bib11], [@bib51] Aberrations of this pathway can lead to a range of human pathologies, including developmental disorders affecting the limbs, as well as neurodevelopmental and psychiatric disorders.[@bib10], [@bib52], [@bib53] There is also significant evidence of the importance of Wnt signaling in developmental eye disorders in mouse models.[@bib54], [@bib55]

*FBXW11* is also involved in Hh signaling by regulating the ubiquitination of GLI transcription factors ([Figures S9](#mmc1){ref-type="supplementary-material"}C and S9D). Variants in Hh pathway genes are associated with developmental anomalies, some of which are comparable to those observed in the individuals presented here. Copy number gains encompassing *BTRC* are linked with developmental limb anomalies.[@bib9], [@bib56] *Drosophila* with mutations in *Slimb,* the ortholog of both *FBXW11* and *BTRC*, develop supernumerary limbs or ectopic legs and eye anomalies.[@bib57], [@bib58], [@bib59] In mice, mutations of GLI transcription factors can cause multiple malformations, including polydactyly, anophthalmia, and coloboma.[@bib60], [@bib61], [@bib62], [@bib63] Finally, in humans, genetic variants affecting members of the Hh signaling pathway, such as *SHH* and *PTCH1* (MIM: [601309](601309){#intref0110}), have been associated with developmental eye anomalies and HPE.[@bib15], [@bib64], [@bib65], [@bib66] *GLI2* (MIM: [165230](165230){#intref0115}) and *GLI3* (MIM: [165240](165240){#intref0120}) variants have also been reported in individuals with a variety of phenotypic features including HPE, polydactyly, and anophthalmia.[@bib67], [@bib68], [@bib69], [@bib70] However, some of the *GLI2* variants have subsequently been classified as benign in ClinVar.

Individual 7 presented with distinctive characteristics of Noonan syndrome, a phenotype linked to RAS-MAPK signaling dysregulation.[@bib71], [@bib72] Ras trafficking and activity are regulated by several mechanisms, including ubiquitination, which can be mediated by different ubiquitin ligase complexes.[@bib73] Recent studies have also identified a circuit involving LZTR1, a Kelch-domain-containing protein altered in Noonan syndrome. LZRT1 functions as a substrate receptor in the cullin 3 ubiquitin ligase complex involved in the ubiquitination and functional down modulation of HRAS.[@bib33], [@bib74], [@bib75] Interestingly, the SCF-β-TrCP E3 ligase complex has also been implicated in the ubiquitination and proteasomal degradation of HRAS,[@bib76] supporting an unanticipated functional link between FBXW11 and RAS signaling modulation warranting further exploration.

Our structural analyses provide evidence of the specific impact of the identified variants on FBXW11 function, as well as for the dominant role of these amino acid changes. Specifically, the variants are predicted to impair proper recognition and/or binding of substrates by the SCF ubiquitin ligase complex. In contrast to the presently reported variants, the two *de novo* changes previously reported in the ASD-affected individuals are predicted to alter protein function by different mechanisms. The exon 3 missense variant is located within the homodimerization domain and might interfere with protein dimerization. Instead, the nonsense substitution affecting exon 4 is predicted to lead to NMD or a truncated protein, potentially reducing the amount of functional protein. Although several of our individuals presented with features of ASD, little clinical information is available for the individuals from these ASD studies, except that the individual carrying the nonsense variant has a high IQ.[@bib28] This limits our ability to suggest further how these alternate mechanisms might contribute to phenotypic variation.

In conclusion, we report seven unrelated individuals presenting with phenotypes including eye, digital, and jaw anomalies, and neurodevelopmental or psychiatric disorders. These individuals all carry *de novo* probably pathogenic missense variants in *FBXW11*, a member of the ubiquitin ligase SCF complex that functions as a regulator of both the Wnt and Hh signaling developmental pathways. *In silico* analyses provide a model for the functional impact of the variants; *in vitro* experiments with human and zebrafish developmental tissue supported early expression of *FBXW11* in relevant structures and *in vivo* zebrafish studies documented the relevance of FBXW11 in developmental processes affected in this phenotypic series. Collectively, these data support the role of *FBXW11* variants in human developmental disorders affecting the brain, eye, jaw, and digits, possibly via modulation of the Wnt/β-catenin, Hh, and RAS signaling pathways.
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